Santarus, Inc. (NASDAQ:SNTS)

CAPS Rating: 2 out of 5

A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.

Recs

0
Player Avatar investorshawn (< 20) Submitted: 11/4/2006 8:18:56 PM : Outperform Start Price: $7.56 SNTS Score: -23.14

Incrementally rising market share in a multi-billion $ market. An effective product with proven advantages over the competition and a brand new distribution deal with Schering-Plough. This is a potential buy-out candidate.

Featured Broker Partners


Advertisement